Healthcare distributor and services company McKesson (NYSE: MCK) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.7% year on year to $105.4 billion. Its non-GAAP profit of $9.93 per share was 4.1% above analysts’ consensus estimates.

Is now the time to buy McKesson? Find out by accessing our full research report, it’s free.

Company Overview

With roots dating back to 1833, making it one of America's oldest continuously operating businesses, McKesson (NYSE: MCK) is a healthcare services company that distributes pharmaceuticals, medical supplies, and provides technology solutions to pharmacies, hospitals, and healthcare providers.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Thankfully, McKesson’s 10.9% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. McKesson’s annualized revenue growth of 14.5% over the last two years is above its five-year trend, suggesting its demand recently accelerated.

We can dig further into the company’s revenue dynamics by analyzing its most important segment, U.S. Pharmaceutical . Over the last two years, McKesson’s U.S. Pharmaceutical revenue averaged 8.5% year-on-year growth. This segment has lagged the company’s overall sales.

This quarter, McKesson reported year-on-year revenue growth of 7.7%, and its $105.4 billion of revenue exceeded Wall Street’s estimates by 1.2%.

Looking ahead, sell-side analysts expect revenue to grow 7.3% over the next 12 months, a deceleration versus the last two years. We still think its growth trajectory is satisfactory given its scale and indicates the market is forecasting success for its products and services.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Adjusted Operating Margin

McKesson’s adjusted operating margin has generally stayed the same over the last 12 months, averaging 1.6% over the last five years. This profitability was lousy for a healthcare business and caused by its suboptimal cost structure.

Looking at the trend in its profitability, McKesson’s adjusted operating margin might have fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.

In Q2, McKesson generated an adjusted operating margin profit margin of 1.3%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.

McKesson’s EPS grew at 15.3% compounded annual growth rate over the last five years, higher than its 10.9% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its adjusted operating margin didn’t improve.

Diving into the nuances of McKesson’s earnings can give us a better understanding of its performance. A five-year view shows that McKesson has repurchased its stock, shrinking its share count by 24.6%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings.

In Q2, McKesson reported adjusted EPS of $9.93, up from $8.26 in the same quarter last year. This print beat analysts’ estimates by 4.1%. Over the next 12 months, Wall Street expects McKesson’s full-year EPS to grow 12.4% from $40.82 to $45.87.

Key Takeaways from McKesson’s Q2 Results

It was good to see McKesson narrowly top analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Overall, this print had some key positives. The stock remained flat at $871.41 immediately after reporting.

Is McKesson an attractive investment opportunity right now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).